History of Changes for Study: NCT00509795

Vascular Endothelial Growth Factor(VEGF)Trap-Eye:Investigation of Efficacy and Safety in Wet Macular Degeneration(AMD) (VIEW1)

Latest version (submitted December 20, 2012) on ClinicalTrials.gov

- A study version is represented by a row in the table.
- Select two study versions to compare. One each from columns A and B.
- Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Si applies to the Protocol section of the study.
- Click "Compare" to do the comparison and show the differences.
- Select a version's Submitted Date link to see a rendering of the study for that version.
- The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version cur
- Hover over the "Recruitment Status" to see how the study's recruitment status changed.
- Study edits or deletions are displayed in ~~red~~.
- Study additions are displayed in *green*.

Study Record Versions

Version	A	B	Submitted Date	Changes
1	○	○	July 31, 2007	None (earliest Version on record)
2	○	○	August 17, 2007	Recruitment Status, Study Status and Contacts/Locations

Version	A	B	Submitted Date	Changes
3	○	○	November 14, 2007	Contacts/Locations and Study Status
4	○	○	December 4, 2007	Study Status and Contacts/Locations
5	○	○	March 13, 2008	Study Status and Eligibility
6	○	○	June 26, 2008	Contacts/Locations, Arms and Interventions, Study Design, Study Status, Outcome Measures Identification
7	○	○	January 22, 2009	Contacts/Locations, Study Status, Arms and Interventions, Outcome Measures, Eligibility and Sponsor/Collaborators
8	◉	○	March 3, 2009	Study Status and Contacts/Locations
9	○	◉	April 28, 2009	Outcome Measures, Arms and Interventions, Study Status, Eligibility, Conditions and Study Id
10	○	○	September 12, 2009	Recruitment Status, Study Status and Contacts/Locations
11	○	○	December 1, 2009	Study Status, Contacts/Locations and Sponsor/Collaborators
12	○	○	January 5, 2011	Study Status
13	○	○	April 18, 2011	Study Status and Study Design
14	○	○	May 4, 2011	Study Status
15	○	○	December 1, 2011	Recruitment Status, Study Status and Sponsor/Collaborators
16	○	○	April 13, 2012	Arms and Interventions, Outcome Measures, Study Status, More Information, Reported Adver Baseline Characteristics, Participant Flow, Eligibility, Study Description and Study Identificatio
17	○	○	December 17, 2012	Reported Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow and
18	○	○	December 20, 2012	Outcome Measures, References and Study Status

Compare | Comparison Format: (•) Merged ( ) Side-by-Side

Scroll up to access the controls

Compare v7 to v8

Changes (Merged) for Study: NCT00509795
March 3, 2009 (v8) -- April 28, 2009 (v9)

Changes in: Outcome Measures, Arms and Interventions, Study Status, Eligibility, Conditions and Study Ide

[ ] **Show only changed modules**

Study Identification

Unique Protocol ID: VGFT-OD-0605

Brief Title: ~~Double-Masked Study of Efficacy and Safety of IVT VEGF Trap-Eye in Subjects With W~~ ~~1) (VIEW1)~~ *Vascular Endothelial Growth Factor(VEGF)Trap-Eye:Investigation of Efficac Wet Age-Related Macular Degeneration(AMD) (VIEW1)*

Official Title: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safet Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Macular Degeneration

Secondary IDs:

Study Status

Record Verification: ~~March 2009~~ *April 2009*

Overall Status: Recruiting

Study Start: August 2007

Primary Completion: ~~October 2010~~ *December 2011* [Anticipated]

Study Completion: ~~January 2012~~ *December 2011* [Anticipated]

First Submitted: July 31, 2007

First Submitted that Met QC Criteria:	July 31, 2007
First Posted:	August 1, 2007 [Estimate]
Last Update Submitted that Met QC Criteria:	~~March 3, 2009~~ *April 28, 2009*
Last Update Posted:	~~March 5~~ *April 29*, 2009 [Estimate]

Sponsor/Collaborators

Sponsor:	Regeneron Pharmaceuticals
Responsible Party:	
Collaborators:	Bayer

Oversight

U.S. FDA-regulated Drug:	
U.S. FDA-regulated Device:	
Data Monitoring:	Yes

Study Description

Brief Summary:	This study is a phase III, double-masked, randomized, study of the efficacy and safety o Eye in patients with neovascular age-related macular degeneration. Approximately 120 be randomized in the US and Canada.
Detailed Description:	

Conditions

Conditions:	~~Neovascular Age-Related~~ Macular Degeneration
Keywords:	

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment

Study Phase:	Phase 3
Interventional Study Model:	Parallel Assignment
Number of Arms:	4
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:	Randomized
Enrollment:	1200 [Anticipated]

Arms and Interventions

Arms	Assigned Interventions

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.